Remix Therapeutics

Remix Therapeutics is a biotechnology business that is working on developing small-molecule medicines to reprogram ribonucleic acid processing and cure disease in novel ways. The company's medicines aid in the identification of patterns in ribonucleic acid processing and their application to control gene expression in order to change the way genes are read from the genome, correcting, enhancing, or eliminating the gene message, allowing healthcare practitioners to address disease causes at their source.

Remix Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $13.5B in funding across 64 round(s). With a team of 51-100 employees, Remix Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Remix Therapeutics, raised $60.0M. Discover more about their projects, partnerships, and impact on our platform.